Vimarsana
Biggest News Aggregation in the World

Well Lysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Well Lysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Well Lysis Today - Breaking & Trending Today

Global Cell Lysis and Disruption Market Research Report - Vimarsana News

Global Cell Lysis and Disruption Market Research Report

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The

How to extract RNA from hard-to-lyse samples in TRIzol - Vimarsana News

How to extract RNA from hard-to-lyse samples in TRIzol

RNA isolation is a challenging procedure. Unlike DNA, which is highly stable, RNA is very unstable, quickly digested by RNase enzymes if their activity isn’t immediately inhibited. One popular reagent in RNA isolation protocols is TRIzol ® . TRIzol was specifically formulated to isolate total RNA from any sample type in the modern research laboratory, whether in academia or industry: cells, hard to ly

Proximity labeling to identify high-confidence SARS-CoV-2 interactors - Vimarsana News

Proximity labeling to identify high-confidence SARS-CoV-2 interactors

A recent report published in the STAR Protocols journal depicted a protocol for an antibody-based proximity labeling to discover biotinylated interactors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

New Spex Genomax 2050 accelerates the extraction of molecules - Vimarsana News

New Spex Genomax 2050 accelerates the extraction of molecules

Obtain fast and efficient extraction of nucleic acids, proteins, and other molecules with the new Spex® Genomax® 2050; a high-throughput plant and animal tissue homogenizer and cell lyser designed for rapid cell disruption, cell lysis and tissue homogenization through bead beating.

Could soluble CD24 offer some hope against severe COVID-19? - Vimarsana News

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.